Skip to main content

Table 3 Comparison of quality of life

From: Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study

  QOL score

n

Pretreatment

Posttreatment

DE + rh-endostatin

35

53.12 ± 3.43

53.18 ± 4.41

DE

33

53.55 ± 4.87

51.76 ± 5.43

  1. Abbreviations: QOL, quality of life; DE, docetaxel and epirubicin.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us